Dr. Reddy’s Laboratories Ltd. (DRL) and OneSource Specialty Pharma have given an endeavor on the Delhi High Court that they may neither sell nor market their model of an anti-obesity drug in India pending the result of a patent infringement lawsuit filed by the Danish pharmaceutical large Novo Nordisk.
The case pertains to an alleged violation of Novo Nordisk’s patent on its diabetes medicine, semaglutide, offered as Wegovy.
Dr. Reddy’s and OneSource, represented by senior advocates Abhishek Manu Singhvi and Mukul Rohatgi, respectively, knowledgeable the court docket that whereas Dr. Reddy’s has been granted a licence to manufacture the contested drug in December 2024 and started manufacturing in April 2025, Dr. Reddy’s at present does not maintain a licence to sell the drug in India.
Dr. Reddy’s and OneSource gave an assurance that they may will not sell the drug in India. However, the Indian parma firms stated they reserve their proper to export the drug in international locations the place Novo Nordisk has not been granted a patent but.
These submissions have been formally taken on file by the court docket, and the counsel for 2 pharma firms confirmed that the endeavor would stay binding on the corporate till the following listening to.
Appearing for Novo Nordisk, senior advocate Sandeep Sethi argued that below the Indian Patents Act, 1970, even exporting a product that infringes a patent constitutes an act of infringement.
The court docket, in its May 29 order, stated it’s going to contemplate the submission of the events on the following date of listening to, on August 19.
Published – May 31, 2025 09:48 pm IST
